Targeting the B-cell lymphoma/leukemia 2 family in cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22649144.
- Also identified by DOI 10.1200/JCO.2011.37.0981 and PMC identifier 4979238.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The B-cell lymphoma/leukemia 2 (BCL-2) family of proteins has attracted the attention of cancer biologists since the cloning of BCL-2 more than 25 years ago. In the intervening decades, the way the BCL-2 family controls commitment to programmed cell death has been greatly elucidated. Several drugs directed at inhibiting BCL-2 and related antiapoptotic proteins have been tested clinically, with some showing considerable promise, particularly in lymphoid malignancies. A better understanding of the BCL-2 family has also provided insight into how conventional chemotherapy selectively kills cancer cells and why some cancers are more chemosensitive than others. Further exploitation of our understanding of the BCL-2 family promises to offer improved predictive biomarkers for oncologists and improved therapies for patients with cancer.
Medical subject headings
- Antineoplastic Agents
- Molecular Targeted Therapy
- Neoplasms
- Proto-Oncogene Proteins c-bcl-2